Phase 4
Completed N=57
Kidney Damage in Patients With Moderate Fall in eGFR
Source: ClinicalTrials.gov NCT01136876 ↗Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcomePrimary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL
Summary
To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration |
-27.76; -11.11; -11.84; -8.23; -27.06; -10.68 | — |
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age and provides informed consent
- Scheduled to undergo percutaneous coronary intervention
- Documented pre-dose Estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.73 m squared and less than or equal to 59 mL/min/1.73 m squared
Exclusion Criteria
- Pregnant or lactating females
- Severe congestive heart failure
- History of hyperthyroidism;
- Unstable renal function
- Emergency PCI
- History of hypersensitivity to iodinated contrast agents
- Receiving diuretics to prevent acute renal injury
Data sourced from ClinicalTrials.gov (NCT01136876). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.